JP2016510028A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510028A5
JP2016510028A5 JP2015560283A JP2015560283A JP2016510028A5 JP 2016510028 A5 JP2016510028 A5 JP 2016510028A5 JP 2015560283 A JP2015560283 A JP 2015560283A JP 2015560283 A JP2015560283 A JP 2015560283A JP 2016510028 A5 JP2016510028 A5 JP 2016510028A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
leukemia
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560283A
Other languages
English (en)
Other versions
JP6266659B2 (ja
JP2016510028A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/018759 external-priority patent/WO2014134201A1/en
Publication of JP2016510028A publication Critical patent/JP2016510028A/ja
Publication of JP2016510028A5 publication Critical patent/JP2016510028A5/ja
Application granted granted Critical
Publication of JP6266659B2 publication Critical patent/JP6266659B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 化合物
    Figure 2016510028
    、またはその薬学的に許容される塩。
  2. 化合物
    Figure 2016510028
  3. 請求項1または2に記載の化合物、及び薬学的に許容される賦形剤を含む、薬学的組成物。
  4. 治療を必要とする対象において治療するための薬学的組成物であって、有効な投薬量の請求項1および2のいずれか一項に記載の化合物を含む、薬学的組成物
  5. 前記癌が、
    (a)癌腫であって、膀胱、乳房、結腸、直腸、腎臓、肝臓、肺、食道、胆嚢、卵巣、膵臓、胃、子宮頚、甲状腺、前立腺、および皮膚の各癌を含むもの
    (b)リンパ系統の造血器腫瘍であって、白血病、急性リンパ球性白血病、慢性骨髄性白血病、急性リンパ芽球性白血病、B細胞リンパ腫、T細胞リンパ腫、ホジキンリンパ腫、非ホジキンリンパ腫、有毛細胞性リンパ腫、バーキットリンパ腫を含むもの
    (c)リンパ系統の造血器腫瘍であって、急性及び慢性骨髄性白血病、骨髄異形成症候群、及び前骨髄球性白血病を含むもの、
    (d)間葉性由来の腫瘍であって、繊維肉腫、及び横紋筋肉腫、並びに他の肉腫であって、軟部組織及び骨肉腫を含むもの、
    (e)中枢及び末梢神経系の腫瘍であって、星状細胞腫、神経芽細胞腫、神経膠腫、及び神経鞘腫を含むもの、
    (f)黒色腫、セミノーマ、奇形癌、骨肉腫、色素性乾皮症(xenoderoma pigmentosum)、角化棘細胞腫、甲状腺濾胞癌、カポジ肉腫、子宮内膜癌、頭頸部癌、膠芽腫、悪性腹水又は造血癌
    より選択される、請求項4に記載の薬学的組成物
  6. 前記癌がリンパ系統の造血器腫瘍である、請求項4に記載の薬学的組成物
  7. 前記癌が軟部組織肉腫である、請求項4に記載の薬学的組成物
  8. 前記癌が乳癌である、請求項4に記載の薬学的組成物
  9. 前記癌が神経膠腫である、請求項4に記載の薬学的組成物
  10. 前記癌が急性骨髄性白血病(AML)である、請求項4に記載の薬学的組成物
  11. 前記癌が黒色腫である、請求項4に記載の薬学的組成物
  12. 前記癌が骨髄異形成症候群である、請求項4に記載の薬学的組成物
  13. 前記癌がp53野生型(p53 WT として特定される、請求項5から12のいずれか一項に記載の薬学的組成物
  14. 前記薬学的組成物が、放射線治療と組み合わせて使用される、請求項5から12のいずれか一項に記載の薬学的組成物。
  15. 前記薬学的組成物が、放射線治療と組み合わせて使用される、請求項13に記載の薬学的組成物。
JP2015560283A 2013-02-28 2014-02-26 癌の治療のための安息香酸誘導体mdm2阻害剤 Active JP6266659B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361770901P 2013-02-28 2013-02-28
US61/770,901 2013-02-28
PCT/US2014/018759 WO2014134201A1 (en) 2013-02-28 2014-02-26 A benzoic acid derivative mdm2 inhibitor for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2016510028A JP2016510028A (ja) 2016-04-04
JP2016510028A5 true JP2016510028A5 (ja) 2017-02-23
JP6266659B2 JP6266659B2 (ja) 2018-01-24

Family

ID=50272765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560283A Active JP6266659B2 (ja) 2013-02-28 2014-02-26 癌の治療のための安息香酸誘導体mdm2阻害剤

Country Status (11)

Country Link
US (1) US8952036B2 (ja)
EP (1) EP2961735B1 (ja)
JP (1) JP6266659B2 (ja)
CN (1) CN105121407B (ja)
AR (1) AR094970A1 (ja)
AU (1) AU2014223547B2 (ja)
CA (1) CA2902856C (ja)
MX (1) MX368703B (ja)
TW (1) TW201505630A (ja)
UY (1) UY35353A (ja)
WO (1) WO2014134201A1 (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
JP6342808B2 (ja) 2011-10-18 2018-06-13 エイルロン セラピューティクス,インコーポレイテッド ペプチドミメティック大環状化合物
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
MX2015012427A (es) 2013-03-14 2016-01-12 Amgen Inc Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
EP3068393B9 (en) 2013-11-11 2022-07-20 Amgen Inc. Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20230119040A (ko) 2015-01-20 2023-08-14 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US9962380B2 (en) * 2015-09-23 2018-05-08 Wisconsin Alumni Research Foundation Methods for treating cognitive deficits associated with fragile X syndrome
CN113788818A (zh) * 2016-04-06 2021-12-14 密执安大学评议会 Mdm2蛋白质降解剂
US10633386B2 (en) * 2016-04-12 2020-04-28 The Regents Of The University Of Michigan BET protein degraders
KR20230127371A (ko) 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
CN110291087B (zh) 2016-12-01 2024-07-09 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
BR112019012682A2 (pt) 2016-12-23 2019-12-17 Arvinas Operations Inc moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CA3049912A1 (en) 2017-01-26 2018-08-02 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
IL278345B2 (en) * 2018-04-30 2024-05-01 Kartos Therapeutics Inc Cancer treatment methods
WO2019224803A2 (en) * 2018-05-25 2019-11-28 Kartos Therapeutics, Inc. Methods of treating myeloproliferative neoplasms
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂,及其制备方法、药物组合物和应用
AU2020336309A1 (en) 2019-08-26 2022-03-17 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
EP4204418A1 (en) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
PE20231555A1 (es) 2020-09-14 2023-10-03 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos
TW202432544A (zh) 2022-09-07 2024-08-16 美商亞文納營運公司 快速加速纖維肉瘤降解化合物及相關使用方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1016828A (en) 1961-11-13 1966-01-12 Mcneilab Inc Substituted morpholines and process for preparing same
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
ATE219077T1 (de) 1994-08-19 2002-06-15 Abbott Lab Endothelin antagoniste
BR9707509A (pt) 1996-02-13 1999-07-27 Abbott Lab Composto composto farmacêutica e processos para antagonizar endotelina para tratar hipertensão insuficiência cardiaca congestiva congestiva restenose emseguida a lessão arterial isquemia cerebral ou miocárdica ou aterosclerose angina coronariana vasosespasmo cerebral insuficiência renal aguda e crônica ulceração gástrica nefrotoxicidade induzida por ciclosporina toxicidade induzida por endotoxina asma distúrbio da lipoproteina relacionados com lpl doenças proliferatives hipertensão pulmonar aguda ou cronica agregação plaquetaria tombose cardiotoxiadade mediada por il-2 noncicepção colite disturbio da permeabulidade vascilar lesão por reperfusão-isquemia doença deraynaud e enxaqueca e para a preparar um composto.
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
SK1452000A3 (en) 1997-08-04 2001-05-10 Abbott Lab Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
WO1999031507A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
EP1358178A2 (en) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
CA2446380A1 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
JP4477351B2 (ja) 2001-12-18 2010-06-09 エフ.ホフマン−ラ ロシュ アーゲー シス−2,4,5−トリフェニル−イミダゾリン類及び腫瘍の処理へのそれらの使用
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
KR100832277B1 (ko) 2004-05-18 2008-05-26 에프. 호프만-라 로슈 아게 신규 cis-이미다졸린
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
AU2006224765B2 (en) 2005-03-16 2012-02-09 F.Hoffmann-La Roche Ag CIS-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments
EP1871369A4 (en) 2005-04-04 2009-11-11 Eisai R&D Man Co Ltd DIHYDROPYRIDINE COMPOUNDS AND COMPOSITIONS FOR HEADACHES
CN101316823B (zh) 2005-12-01 2013-05-22 霍夫曼-拉罗奇有限公司 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
AU2007269836A1 (en) 2006-06-30 2008-01-10 Albany Molecular Research, Inc. Substituted piperidines that increase P53 activity and the uses thereof
JP2009543865A (ja) 2006-07-19 2009-12-10 ユニバーシティ オブ ジョージア リサーチ ファウンデーション, インコーポレーテッド ピリジノンジケト酸:併用療法におけるhiv複製の阻害剤
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
CA2701932C (en) 2007-10-09 2015-10-20 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US20100256191A1 (en) 2007-12-26 2010-10-07 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
JP2011514364A (ja) 2008-03-21 2011-05-06 クロリオン ファーマ,インコーポレーテッド 置換されたピロリジン及びピペリジン化合物、その誘導体、並びに疼痛を治療するための方法
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
AU2009294673B2 (en) 2008-09-18 2014-08-14 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
WO2011023677A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US20120046306A1 (en) * 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2016510028A5 (ja)
HRP20202065T1 (hr) Kristalni oblik inhibitora mdm2
JP2012082234A5 (ja)
RU2441005C2 (ru) Новые пиразолопиримидины как ингибиторы циклинзависимых киназ
JP2017517506A5 (ja)
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
JP2017516775A5 (ja)
FI3694529T3 (fi) Trispesifiset proteiinit ja niiden käyttömenetelmät
PE20221259A1 (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras
MX2017012965A (es) Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo.
HRP20240055T1 (hr) Derivati piperidinona kao inhibitori mdm2 za liječenje raka
JP2016106149A5 (ja)
JP2016501221A5 (ja)
JP2015534578A5 (ja)
JP2016536286A5 (ja)
WO2015103438A3 (en) Oncolytic virus adjunct therapy with agents that increase virus infectivity
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
RU2019114963A (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
MX2016010683A (es) Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
IL290415A (en) Compounds with deuterium for use in cancer treatment
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
RU2016132635A (ru) Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия
RU2018102963A (ru) Производные анилинпиримидина и их применения
EA201892746A1 (ru) Лечение гематологической злокачественной опухоли с помощью 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
JP2017530983A5 (ja)